Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1

Interventions

Cyclophosphamide 10Irinotecan 8Melphalan 7Vincristine 6Temozolomide 6Doxorubicin 6Busulfan 6Topotecan 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Ifosfamide 4Filgrastim 4Etoposide 4Albumin-Bound Paclitaxel 4Trabectedin 3Sirolimus 3Nivolumab 3130-nm albumin-bound paclitaxel 3pegfilgrastim 2olaparib 2fludarabine phosphate 2fludarabine 2eribulin 2cixutumumab 2abemaciclib 2X-Rays 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Ewing × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡